company background image
VNRX logo

VolitionRx NYSEAM:VNRX Stock Report

Last Price

US$0.59

Market Cap

US$53.7m

7D

-4.8%

1Y

-39.8%

Updated

11 Mar, 2025

Data

Company Financials +

VNRX Stock Overview

A multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. More details

VNRX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

My Notes

Capture your thoughts, links and company narrative

VolitionRx Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for VolitionRx
Historical stock prices
Current Share PriceUS$0.59
52 Week HighUS$1.09
52 Week LowUS$0.43
Beta1.1
1 Month Change-1.67%
3 Month Change-9.37%
1 Year Change-39.80%
3 Year Change-75.72%
5 Year Change-76.31%
Change since IPO-80.33%

Recent News & Updates

Recent updates

Shareholder Returns

VNRXUS Medical EquipmentUS Market
7D-4.8%-5.7%-4.6%
1Y-39.8%3.7%8.8%

Return vs Industry: VNRX underperformed the US Medical Equipment industry which returned 3.7% over the past year.

Return vs Market: VNRX underperformed the US Market which returned 8.8% over the past year.

Price Volatility

Is VNRX's price volatile compared to industry and market?
VNRX volatility
VNRX Average Weekly Movement11.2%
Medical Equipment Industry Average Movement8.5%
Market Average Movement6.3%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market3.3%

Stable Share Price: VNRX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: VNRX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a96Cameron Reynoldswww.volition.com

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu Q Vet, a cancer screening test for dogs and other animals; Nu

VolitionRx Limited Fundamentals Summary

How do VolitionRx's earnings and revenue compare to its market cap?
VNRX fundamental statistics
Market capUS$53.75m
Earnings (TTM)-US$29.87m
Revenue (TTM)US$1.29m

42.5x

P/S Ratio

-1.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VNRX income statement (TTM)
RevenueUS$1.29m
Cost of RevenueUS$0
Gross ProfitUS$1.29m
Other ExpensesUS$31.16m
Earnings-US$29.87m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.32
Gross Margin100.00%
Net Profit Margin-2,323.23%
Debt/Equity Ratio-21.2%

How did VNRX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/11 00:14
End of Day Share Price 2025/03/11 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

VolitionRx Limited is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raymond MyersBenchmark Company
Jan WaldBenchmark Company
Bruce JacksonBenchmark Company